1-benzyl-3-methyloxycarbonyl-4-(4-chlorophenyl)pyrrolidine | 438492-34-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 1-benzyl-3-methyloxycarbonyl-4-(4-chlorophenyl)pyrrolidine
• 英文别名: Trans-methyl 1-benzyl-4-(4-chlorophenyl)pyrrolidine-3-carboxylate；methyl 1-benzyl-4-(4-chlorophenyl)pyrrolidine-3-carboxylate
• CAS: 438492-34-3
• 化学式: C₁₉H₂₀ClNO₂
• 分子量: 329.826
• InChiKey: JLPPICQAWSOLCD-UHFFFAOYSA-N

物化性质

• 沸点：
  426.2±45.0 °C(Predicted)
• 密度：
  1.213±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  methyl 3-(4-chlorophenyl)propenoate 、 N,N-bis(tosylmethyl)benzylamine 在 六甲基磷酰三胺 、 samarium diiodide 作用下， 以 四氢呋喃 为溶剂， 以63%的产率得到1-benzyl-3-methyloxycarbonyl-4-(4-chlorophenyl)pyrrolidine
  参考文献：
  名称：

  3-烷氧基羰基吡咯烷衍生物的简便合成

  摘要：

  摘要 在二碘化钐存在下，通过 α,β-不饱和酯与不稳定的偶氮甲碱叶立德的 1,3-偶极环加成反应，可以很容易地获得一系列 3-烷氧基羰基吡咯烷衍生物。

  DOI：

  10.1081/scc-120002708

文献信息

• [EN] PYRROLIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE PYRROLIDINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011085886A1

  公开（公告）日：2011-07-21

  The present invention relates to compounds of formula (I) or to a pharmaceutically active salt thereof. It has been found that the present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).

  本发明涉及式(I)的化合物或其药用活性盐。已发现这些化合物是治疗抑郁症、疼痛、精神病、帕金森病、精神分裂症、焦虑和注意力缺陷多动障碍（ADHD）的高潜力NK-3受体拮抗剂。
• PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2398768A1

  公开（公告）日：2011-12-28
• PYRROLIDINE DERIVATIVES
  申请人：F.Hoffmann-La Roche AG

  公开号：EP2513052A1

  公开（公告）日：2012-10-24
• [EN] PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE PYRROLIDINE EN TANT QU'ANTAGONISTES DU RÉCEPTEUR NK3
  申请人：HOFFMANN LA ROCHE

  公开号：WO2010094667A1

  公开（公告）日：2010-08-26

  The present invention relates to a compounds of formula I wherein A is -NR'-, -S-, -S(O)- or -S(O)2-; R' is hydrogen or lower alkyl; Ar is aryl or is a five or six membered heteroaryl group, containing one or two N-atoms; R is a five or six membered heterocyclic group X1 is N or CH; and X2 is -N(R1)-, -CH2-, -O-, -S-, -S(O)-, or -S(O)2-, R1 is hydrogen, lower alkyl, S(O)2-lower alkyl, C(O)-lower alkyl, C(O)-cycloalkyl optionally substituted by lower alkyl; with the proviso that at least one of X1 or X2 contains a heteroatom, or is a five or six membered heteroaryl group, containing one or two N-atoms, which groups are unsubstituted or may be substituted by one or two R1; wherein R1 is lower alkyl or cyano; R2 is lower alkyl substituted by halogen, halogen, cyano or nitro; R3 is halogen; R4 is hydrogen or lower alkyl; o is 1 or 2; in case o is 2, R2 may be the same or different; p is 1 or 2; in case p is 2, R3 may be the same or different; or to a pharmaceutically active salt thereof. It has been found that the present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, bipolar disorders, anxiety and attention deficit hyperactivity disorder (ADHD).